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Abstract
Background:  Chondrodystrophic myotonia or Schwartz-Jampel syndrome is a rare genetic
disorder characterized by myotonia and skeletal dysplasia. It may be progressive in nature.
Recently, the gene responsible for Schwartz-Jampel syndrome has been found and the defective
protein it encodes leads to abnormal cartilage development and anomalous neuromuscular activity.
Case Presentation: We report the clinical findings and the management of an 8-year-old boy
with this disorder. The molecular findings confirm that the patient is a compound heterozygote
with a different splicing mutation in each Perlecan allele. This resulted in a significant reduction in
the production of the encoded normal protein.
Conclusion: We discuss the multi-disciplinary management of Schwartz-Jampel syndrome that will
facilitate optimal care and timely intervention of patients with this disorder.
Background
In 1962, Oscar Schwartz and Robert Jampel jointly
described a rare autosomal recessive disorder in a pair of
siblings. The children had short stature, myotonia with
paucity of facial expression, blepharophimosis, pectus
carinatum, and contractures. [1] This disorder was also
designated osteo-chondro-muscular dystrophy or chon-
drodystrophic myotonia, [2] and it was initially thought
to be neurogenic in etiology. Recently, mutations in the
gene Perlecan (HSPG2) encoding the protein heparan sul-
fate proteoglycan 2, have been found to be responsible for
this condition. Perlecan resides in 1p34-p35.1. Its attend-
ant defect leads to abnormal cartilage development and
anomalous neuromuscular activity, resulting in skeletal
dysplasia and electrophysiologic signs of myotonia as
seen in chondrodystrophic myotonia or Schwartz-Jampel
syndrome (SJS). [3,4]
We report the case of an 8-year-old boy with SJS associated
with Perlecan mutations. We discuss the clinical features,
molecular findings, and management of this disorder.
Case Presentation
An 8-year-old Caucasian boy presented with distinctive
facial features, mild generalized muscle weakness and
muscle stiffness. He was born to healthy, non-consan-
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guineous parents. He started walking at the age of 16–18
months. His mother expressed concern about the unusual
positioning of his legs and feet. At the age of 3 years, the
patient was noted to have distinctive facies and skeletal
abnormalities, which became increasingly apparent and
progressive with time. There was no family history of neu-
romuscular disorders or skeletal dysplasias.
Because his main complaint was generalized muscle stiff-
ness, he was prescribed carbamazepine 600 mg in the
morning and 700 mg in the evening. Having a warm bath
twice a day also help in alleviating his stiffness. Gradually,
he experienced mild muscle weakness in his lower extrem-
ities resulting in inability to get up from the floor. He
expressed difficulty in climbing stairs and running. One
positive aspect was that his frequency of falls had reduced.
Physical examination revealed a boy with unusual facies
and stiffness. His height was 122 cm (15th percentile),
weight 25.3 kg (50th), and head circumference 54.3 cm
(90th). He was normotensive. His distinctive facial fea-
tures included blepharophimosis, low set ears with folded
helices, a fixed facial expression due to tonic contraction
of the facial muscles, pursed lips caused by contraction of
the perioral muscles, and micrognathia (figure 1). He was
mildly myopic. His palate was highly arched. He had a
high-pitched voice and a drooling indistinct speech.
The patient had kyphosis of his cervical spine, pes planus
of his feet, and valgus deformities of his ankles. Also
noted was a tendon contracture of his left Achilles heel.
He had diffuse muscular hypertrophy and stiffness but
generalized myotonia was not evident. Strength testing
revealed grade 5 muscle power (normal) throughout.
Reflexes were difficult to elicit, especially in the lower
extremities. He had a crouching stance and a stiff gait.
When he walked, he would circumduct his right leg.
Examination of his genitalia revealed small testes. His
mental development was mildly delayed.
Skeletal survey showed kyphoscoliosis, bowing of long
bones and abnormal capital femoral epiphyses. His blood
differential and chemistry were normal, with the excep-
tion of creatine kinase, which was elevated at 896 I/U. The
electromyogram showed occasional myotonic discharges.
The muscle biopsy was unremarkable. The clinical diag-
nosis was SJS and the molecular analysis confirmed com-
pound heterozygozity with different splice-site mutations
in the two Perlecan alleles. These mutations result in sig-
nificant reduction in the production of the wild-type (nor-
mal) protein encoded by Perlecan (figure 2).
The patient was placed on carbamazepine (Tegretol XR)
600 mg manè and 700 mg noctè for muscle stiffness and
referred for physical therapy. His generalized muscle stiff-
ness showed symptomatic alleviation with car-
bamazepine treatment. His family was cautioned
regarding life-threatening complications that may arise
during anesthesia. Apart from neuromuscular assess-
ments, he was also managed by routine evaluations in the
orthopedic, ophthalmologic, and pediatric clinics.
Discussion
Chondrodystrophic myotonia or Schwartz-Jampel syn-
drome (SJS) is a rare skeletal dysplasia often associated
with clinical or electrophysiologic signs of myotonia. It
may be progressive in nature. To date, there had been sev-
eral reports on Middle Eastern families and South African
kindreds, the prevalence of which may be accounted for
by parental consanguinity in these regions. [5] The char-
acteristic features include myotonia with a fixed or frozen
facial expression, pursed lips, and a small mouth. The
ocular manifestations are blepharophimosis, myopia and
medial displacement of outer canthi. Patients have a wad-
dling gait and frequently adopt a crouched stance because
of joint stiffness. The skeletal findings are short stature,
pectus carinatum, kyphoscoliosis, platyspondyly with
coronal clefts in the vertebrae, metaphyseal and epiphy-
seal dysplasias, and joint contractures. Respiratory and
feeding difficulties may occur shortly after birth. Mild
mental retardation, which may be intrinsic to the syn-
drome or a result of the severity of physical limitations,
has been said to be present in about 25% of cases. Muscle
hypertrophy is evident in most patients. Malignant hyper-
thermia during anesthesia is a potentially lethal hazard.
[5] In the prenatal period, polyhydramnios and absence
of a stomach bubble, both indicative of a swallowing dis-
order, may be noted. [6] Contractures or short femurs may
also be found on ultrasound. [6]
There is considerable clinical heterogeneity in the SJS phe-
notype. Giedion et al. (1997) proposed a useful clinico-
radiological classification, characterizing the SJS pheno-
type into type 1A, which is associated with moderate bone
dysplasia and is cognizant in childhood; type IB, which
shows more severe bone dysplasia and is recognizable at
birth; and type 2, which has marked bowing of long bones
and is manifested at birth. While types 1A and 1B are
caused by mutations in Perlecan at 1p36.1, type 2 shows
no linkage to the SJS locus on chromosome 1. [7] Type 2
is now identified as Stüve-Wiedemann syndrome, a genet-
ically distinct, and highly lethal disorder. [4]
Creatine kinase and other muscle enzymes may be mildly
or moderately elevated. [2,5] The electromyography
shows persistent spontaneous activity that wanes at rest.
Muscle biopsies show no distinguishable findings. [5]
Perlecan mutations characterized thus far in patients with
SJS were missense mutations, splicing mutations withBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/3
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The patient has blepharophimosis, pursed lips, low-set ears, and stiffness of facial expression Figure 1
The patient has blepharophimosis, pursed lips, low-set ears, and stiffness of facial expression. Note the bowing of the tibiae, 
valgus deformities of the ankles, and pes planus. Also note the muscle hypertrophy and mild chest deformity.BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/3
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exon skipping, and deletions.[3,4] In these patients,
mutant Perlecan molecules or reduced amounts of wild-
type Perlecan are secreted in the tissue matrix. Functional
null mutations in the Perlecan were also found in individ-
uals with dyssegmental dysplasia (Silverman-Handmaker
type), a neonatal lethal skeletal dysplasia with exenceph-
aly. Patients with this disorder demonstrated absence of
Perlecan in the cartilage matrix. [8] It would seem that
there is a spectrum of Perlecan disorders with SJS at the
moderate severe area and the lethal Silverman-Hand-
maker syndrome at the most extreme end.
Muscle contraction is initiated at sites of nerve-muscle
contact or neuromuscular junctions. Acetylcholinesterase
degradates the neurotransmitter acetylcholine by hydro-
lyzing it at the synapse, thereby terminating neurotrans-
mission. Peng et al. (1999) demonstrated that perlecan in
vitro binds to acetylcholinesterase, and postulated that the
perlecan-dystroglycan complex may function as an accep-
tor molecule for acetylcholinesterase at the neuromuscu-
lar junction. [9] Arikawa-Hirasawa et al. (2002) have
shown that in perlecan-null mice, agrin and acetylcholine
molecules were present at the neuromuscular junction but
acetylcholinesterase was totally absent, indicating that
Immunostaining of perlecan with domain-specific anti-perlecan antibodies in muscle tissues from patient and from an unaffected  control subject Figure 2
Immunostaining of perlecan with domain-specific anti-perlecan antibodies in muscle tissues from patient and from an unaffected 
control subject. Staining in muscle tissue of patient is significantly reduced.
Patient (Domain V) Control
Patient (Domain III) ControlBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/3
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perlecan binds acetylcholinesterase and localizes it at the
synapse. [10]
In our patient, the diminished amounts of normal perle-
can found may result in reduced clustering of acetylcho-
linesterase at the neuromuscular junction. This
culminates in a lower inhibition and therefore a higher
concentration of acetylcholine, enhancing neuro-excita-
tory activity and probably generating myotonic
discharges.
Currently, treatment for patients with SJS is primarily
symptomatic, aimed at alleviating symptoms and prevent-
ing or managing complications. The management of con-
tractures, bony deformities, and ambulatory issues will
call for physical therapy, occupational therapy, ortho-
pedic assessment and surgery. [2,5] Ophthalmologic cor-
rection of ptosis, myopia, and juvenile cataract, as well as
repair of the narrowed palpebral fissures may be war-
ranted to facilitate normal vision. [6] Elevation of the
upper eyelid margin by levator aponeurosis surgery may
improve facial appearance and self-image. Myotonia may
respond to phenytoin, procainamide or carbamazepine.
Treatment with carbamazepine, initiated in infancy, can
produce marked resolution and continuous improvement
of myotonia, blepharospasm and joint stiffness, resulting
in lessening of the chest deformity and contractures. [11]
The contractures are progressive until mid-adolescence
but thereafter, usually become static. [5] The myotonia
may improve spontaneously in later childhood.
Individuals with SJS should be cautioned regarding life-
threatening complications that may arise during anesthe-
sia. Micrognathia and jaw muscle rigidity may pose
mechanical difficulties during intubation. Higher doses of
muscle relaxants such as rocuronium may be required to
facilitate tracheal intubation, probably because of the
lowered degradation rate of acetylcholine. [12] Malignant
hyperthemia during anesthesia is a potentially lethal com-
plication. In view of the autosomal recessive mode of
inheritance of this disorder, genetic counseling may be
appropriate as the risk of recurrence is 25% or 1 in 4.
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